CR	complete response
CT	computer tomography
CTLA-4	cytotoxic T-lymphocyte–associated protein 4
EGFR	epidermal growth factor receptor
EMA	European Medicines Agency
FDA	Food and Drug Administration
[18F]FDG	2-deoxy-2-[18F]fluoro-D-glucose
ICIs	immune checkpoint inhibitors
IHC	immunohistochemistry
irAE	immune-related adverse event
mAb	monoclonal antibody
MHC-I or -II	major histocompatibility complex-I or -II
MR	magnetic resonance
OS	overall survival
PD	progressive disease
PD-1	programmed cell death protein 1
PD-L1	programmed cell death ligand 1
PD-L2	programmed cell death ligand 2
PERCIMT	PET Response Evaluation Criteria for Immunotherapy
PERCIST	positron emission tomography response criteria in solid tumors
PET	positron emission tomography
PFS	progression free survival
PR	partial response
RECIST	response evaluation criteria in solid tumors
SD	stable disease
SUV	standardized uptake value
TCR	T cell receptor
TKI	tyrosine kinase inhibitors
TMB	tumor mutational burden
TME	tumor microenvironment
TPS	tumor proportion score